JP2022513888A5 - - Google Patents
Info
- Publication number
- JP2022513888A5 JP2022513888A5 JP2021534270A JP2021534270A JP2022513888A5 JP 2022513888 A5 JP2022513888 A5 JP 2022513888A5 JP 2021534270 A JP2021534270 A JP 2021534270A JP 2021534270 A JP2021534270 A JP 2021534270A JP 2022513888 A5 JP2022513888 A5 JP 2022513888A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable proprotein
- polypeptide
- proprotein
- variant
- masking portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024159011A JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779793P | 2018-12-14 | 2018-12-14 | |
| US62/779,793 | 2018-12-14 | ||
| PCT/US2019/066287 WO2020123980A1 (en) | 2018-12-14 | 2019-12-13 | Il-15 compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159011A Division JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513888A JP2022513888A (ja) | 2022-02-09 |
| JP2022513888A5 true JP2022513888A5 (enExample) | 2022-12-06 |
| JP7557465B2 JP7557465B2 (ja) | 2024-09-27 |
Family
ID=71075819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534270A Active JP7557465B2 (ja) | 2018-12-14 | 2019-12-13 | Ｉｌ－１５組成物およびその使用方法 |
| JP2024159011A Pending JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159011A Pending JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230045048A1 (enExample) |
| EP (1) | EP3893917A4 (enExample) |
| JP (2) | JP7557465B2 (enExample) |
| KR (1) | KR102911817B1 (enExample) |
| CN (1) | CN114746105A (enExample) |
| AU (1) | AU2019395266A1 (enExample) |
| CA (1) | CA3121813A1 (enExample) |
| WO (1) | WO2020123980A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US20230250193A1 (en) * | 2020-06-17 | 2023-08-10 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| US20240228585A1 (en) * | 2021-05-03 | 2024-07-11 | President And Fellows Of Harvard College | Fc-fusion protein therapeutic for the treatment of pancreatitis |
| US20240182537A1 (en) * | 2022-08-31 | 2024-06-06 | Proviva Therapeutics (Hong Kong) Limited | Il-15 procytokine antibody fusion proteins |
| WO2024054425A1 (en) * | 2022-09-08 | 2024-03-14 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| WO2024216170A2 (en) * | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025085744A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Fusion polypeptides and uses thereof |
| WO2025180355A1 (zh) * | 2024-02-27 | 2025-09-04 | 江苏奥赛康生物医药有限公司 | Il-15前药与免疫检查点抑制剂的组合 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| PT1527100E (pt) * | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2016004383A1 (en) * | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| CN107709356A (zh) | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| JP2019519516A (ja) * | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| MY203000A (en) * | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| EP3568474A1 (en) * | 2017-01-10 | 2019-11-20 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
-
2019
- 2019-12-13 WO PCT/US2019/066287 patent/WO2020123980A1/en not_active Ceased
- 2019-12-13 CN CN201980082406.XA patent/CN114746105A/zh active Pending
- 2019-12-13 AU AU2019395266A patent/AU2019395266A1/en not_active Abandoned
- 2019-12-13 EP EP19897286.1A patent/EP3893917A4/en active Pending
- 2019-12-13 CA CA3121813A patent/CA3121813A1/en active Pending
- 2019-12-13 KR KR1020217018990A patent/KR102911817B1/ko active Active
- 2019-12-13 US US17/413,786 patent/US20230045048A1/en active Pending
- 2019-12-13 JP JP2021534270A patent/JP7557465B2/ja active Active
-
2024
- 2024-09-13 JP JP2024159011A patent/JP2024175026A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513888A5 (enExample) | ||
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| ES2962675T3 (es) | Anticuerpos tetravalentes biespecíficos y procedimientos para la fabricación y utilización de los mismos | |
| JP6581985B2 (ja) | ｇｐＡ３３及びＣＤ３に結合二重特異性１価ダイアボディ、並びにその使用 | |
| US20210355219A1 (en) | Conditionally activated target-binding molecules | |
| JP2019513014A5 (enExample) | ||
| US20220098274A1 (en) | Engineered pd-1 variants | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| RU2016106115A (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения | |
| US20230174666A1 (en) | Anti-cd26 proteins and uses thereof | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JP2016525551A5 (enExample) | ||
| CN103687879A (zh) | 多价抗原结合fv分子 | |
| US20220275093A1 (en) | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide | |
| US12590159B2 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| US20200407450A1 (en) | Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regimen to treat cancer | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JP2022548364A5 (enExample) | ||
| JP2022514615A (ja) | ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法 | |
| JP2023518835A (ja) | 制御性ｔ細胞の除去用の二重特異性融合タンパク質 | |
| Chowdhury et al. | Molecular Chimera in Cancer Drug Discovery: Beyond Antibody Therapy, Designing Grafted Stable Peptides Targeting Cancer | |
| WO2026024863A2 (en) | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists | |
| JP2024541136A5 (enExample) |